Multiple Myeloma Treatment

CE / CME

Overcoming Barriers to Effective Treatment and Enrollment in Clinical Trials for Black and Underserved Patients with Multiple Myeloma

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: May 31, 2023

Expiration: May 30, 2024

Frances (Blevins) Arters
Frances (Blevins) Arters, PA-C
Ajay K. Nooka
Ajay K. Nooka, MD, MPH, FACP
Bhavesh Shah
Bhavesh Shah, R.Ph, BCOP
Raphael Szalat
Raphael Szalat, MD, PhD

Pretest

Progress
1 2
Course Completed
1.

Which of the following is true regarding the general presentation and disease course of multiple myeloma? 

2.

Compared to white patients with multiple myeloma, which of the following is associated with Black race?

3.

On a scale of 1-5, how would you rate your confidence in implementing strategies to mitigate barriers to clinical trial enrollment for black patients? 

4.

Which of the following has been found to be an adverse reaction to drug therapy that is more frequent in black compared to whites? 

5.

John is a 69-year-old man with multiple myeloma. He has previously received an immunomodulatory agent, a proteasome inhibitor, a CD38-targeting monoclonal antibody and an alkylating agent, but he currently presents with another relapse. Which of the following would you observe for this patient at this time? 

6.

On a scale of 1-5, how confident are you in your knowledge of racially unique adverse drug events associated with treatment for Black patients with multiple myeloma? 

7.

Blacks represent roughly 20% of all patients with multiple myeloma. What percentage of patients in multiple myeloma clinical trials is represented by blacks? 

8.

On a scale of 1-5, how would you rate your confidence in using BCMA-targeted therapies for treatment of multiple myeloma? 

9.

Jane is a 58-year-old Black woman with relapsed/refractory multiple myeloma. She has been on therapy for MM for 4 years, and presents with a relapse while on her current treatment. You might consider a BCMA-targeted agent if this patient has already tried how many lines of previous therapy?

10.

Which of the following would be appropriate for overcoming racial disparities in multiple myeloma care?